medigraphic.com

2021, Number 2

<< Back Next >>

Rev Cuba Endoc 2021; 32 (2)

Nodular thyroid disease in people diagnosed with acromegaly

Robles TE, Carrasco PIA, Dominguez AE, Leal CL, Torres HOF, Turcios TSE

Language: Spanish
References: 45
Page:
PDF size: 179.56 Kb.


ABSTRACT

The appearance of thyroid nodules in people with acromegaly is a consequence of chronic elevation of growth hormone (GH) and insulin-like growth factor type 1 (IGF-1). Its nature varies according to the geographical area, the iodine sufficiency and family pathological history, among other factors. No Cuban studies on thyroid nodular disease (TND) in these people have been published.
Objectives: Describe some clinical characteristics, as well as biochemical and ultrasonographic ones related to the thyroid gland, according to the presence or not of TND, and to identify the possible association of clinical, biochemical, ultrasonographic and cytological factors with the different types of TND in patients with acromegaly.
Methods: A descriptive, cross-sectional observational study that included 73 patients with acromegaly between January 2003 and December 2017. The following variables were studied: age, sex, skin color, family history of TND, GH levels, thyroid stimulating hormone, free T4, antibodies against thyroid peroxidase and thyroglobulin, thyroid volume, nodular ultrasound pattern and cytological study.
Results: TND occurred in 75.3 % of cases, with a predominance of multinodular goiter. The age at diagnosis time was lower in patients with TND (43.53 ± 9.67) than in those who did not have it (49.33 ± 6.96 years) (p=0.02). GH at diagnosis time of acromegaly was lower in patients with TND (18.73±11.33μg/L vs 35.91±21.68μg/L; (p=0.00). The thyroid volume showed significant differences between both groups (14.2±4.5mL in positive cases of TND and 10.5±2.8mL in negative cases; p=0.002), being the most frequent the nodule with low suspicion of malignancy. The rest of the variables were similar between patients with and without TNDs. Cytology was reported as benign in 75% in single nodules, 80% of nodular goiters and 90% of multinodular goiters (p=0.51).
Conclusions: TND was frequent in cases of acromegaly, and was associated with lower age and lower GH levels at diagnosis time. Multinodular goiter was the most frequent clinical form and hormonal and autoimmunity parameters were not associated with the type of TND.


REFERENCES

  1. Lavrentaki A, Paluzzi A, Wass J, Karavitaki N: Epidemiology of acromegaly: review of population studies. Pituitary 2017;20:4-9.

  2. Vilar L, Vilar C, Lyra R, Naves L: Acromegaly: clinical features at diagnosis. Pituitary 2017;20:22-32.

  3. Reverter J, Fajardo C, Resmini E, Salinas I, Mora M, Llatjós M, et al. Benign and Malignant Thyroid Disease in Acromegaly. Plos One. 2014;9(8):1-6.

  4. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509-17.

  5. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-52.

  6. Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25(3):240-5.

  7. Kasagi K, Shimatsu A, Miyamoto S, Misaki T, Sakahara H, Konishi J. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid. 1999;9(8):791-6.

  8. Cheung N, Boyages S. The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf). 1997;46(5):545-9.

  9. Rogozinsky A, Furioso A, Glikman P, Junco M, Laudi R, Reyes A. Thyroid nodules in acromegaly. Arq Bras Endocrinol Metab. 2012;56(5):300-4.

  10. Tramontano D, Cushing G, Moses A, Ingbar S. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology. 1986;119:940-2.

  11. Aydin K, Aydin C, Dagdelen S, Tezel G, Erbas T. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly. Exp Clin Endocrinol Diabetes. 2016;124:198-202.

  12. Kim H, Lee J, Park M, Cho J, Yoon J, Kim S, et al. Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. PLoS One. 2014;9:e110241. DOI: https://doi.org/10.1371/journal.pone.0110241

  13. Mian C, Ceccato F, Barollo S, Watutantrige-Fernando S, Albiger N, Regazzo D, et al. AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One. 2014;9:e101560. DOI: https://doi.org/10.1371/journal.pone.0101560

  14. Tirosh A, Shimon I. Complications of acromegaly: thyroid and colon. Pituitary 2017;20(1):70-75.

  15. Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T. Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine. 2014;45:114-21.

  16. Gadelha M, Kasuki L, Lim D, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update Endocrine Reviews. 2019;40(1):268-332.

  17. Wolinsky K, Czarnywojtek A, Ruchala M. Nodular Goiter and Thyroid Cancer in Acromegaly. Plos One. 2014;9(2):1-7.

  18. Dal J, Leisner M, Hermansen K, Farkas D, Bengtsen M, Kistorp C, et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab. 2018;103(6):2182-8.

  19. Orme S, McNally R, Cartwright R, Belchetz P. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998;83(8):2730-4.

  20. Dos Santos M, Nascimento G, Nascimento A, Carvalho V, Lopes M, Montenegro R, et al. Thyroid cancer in patients with acromegaly: a case-control study. Pituitary. 2013;16:109-14.

  21. Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary. 2014;17(4):299-306.

  22. Jung CK, Little MP, Lubin JH: The increase in thyroid cancer incidence during the last 4 decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99: 276-85.

  23. Katznelson L, Laws E, Melmed S, Molitch M, Murad M, Utz A, Wass J. Acromegaly: An Endocrine Society Clinical Practice Guideline. JCEM. 2014;99(11):3933-51.

  24. Boguszewski C, Ayuk J. Management of endocrine disease: acromegaly and cancer: an old debate revisited. Eur J Endocrinol. 2016;175(4):147-56.

  25. Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008;55(1):67-71.

  26. Leenhardt L, Grosclaude P, Chérié-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14(12):1056-60.

  27. Terry B. Consideraciones epidemiológicas de los desórdenes por deficiencia de yodo, criterios de evaluación y control. Rev Cubana Hig Epidemiol. 2008[acceso:19/01/2018];46(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S156130032008000300010&lng=es&nrm=iso&tlng=es

  28. Jallad R, Bronstein M. The place of medical treatment of acromegaly: current status and perspectives. Expert Opin Pharmacother. 2013;14:1001-15.

  29. Shaha A. Recurrent differentiated thyroid cancer. Endocr Pract. 2012;18:600-3.

  30. Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.

  31. Cibas E. Ali S. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009;9(11):1159-65.

  32. Wolinski K, Stangierski A, Gurgul E, Brominska B, Czarnywojtek A, Lodyga M, et al. Thyroid lesions in patients with acromegaly - case-control study and update to the meta-analysis. Endokrynol Pol. 2017;68(1):2-6.

  33. de Melo H, Balarini G, Lugarinho L, Sieiro P, Aquino S, Vaisman M, et al. Prevalence of thyroid diseases in patients with acromegaly-Experience of a Brazilian center. Arq Bras Endocrinol Metab. 2013;57(9):685-90.

  34. Herrmann B, Baumann H, Janssen O, Gorges R, Schmid K, Mann K. Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes. 2004;112(5):225-30.

  35. Roelfsema F, Biermasz N, Frolich M, Veldhuis J, Romijn J. Diminished and irregular thyrotropin secretion with preserved diurnal rhythm in patients with active acromegaly. J Clin Endocrinol Metab. 2009;94(6):1945-50.

  36. Turcios S, Lence-Anta J, Santana J, Pereda C, Velasco M, Chappe M. Thyroid Volume and Its Relation to Anthropometric Measures in a Healthy Cuban Population. Eur Thyroid J. 2015;4(1):55-61.

  37. Manavela M, Vigovich C, Dilewicz K, Juri A, Miechi L, Fernandez V, et al. Thyroid autoimmune disorders in patients with acromegaly. Pituitary 2015;18(6):912-5.

  38. Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448-57.

  39. Giustina A, Barkan A, Beckers A, Biermasz N, Biller B, Boguszewski C, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab 2020;105(4). DOI: https://doi.org/10.1210/clinem/dgz096

  40. Lai N, Garg D, Heaney A, Bergsneider M, Leung A. No benefit of dedicated thyroid nodule screening in patients with acromegaly. Endocr Pract. 2020;26(1):16-21.

  41. Fleseriu M, Biller B, Freda P, Gadelha M, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1-13

  42. Ruchala M, Wolinski K. Health-Related Complications of acromegaly-risk of malignant neoplasms. Front Endocrinol (Lausanne). 2019;10:268. DOI: https://doi.org/10.3389/fendo.2019.00268

  43. Gullu B, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary. 2010;13(3):242-8.

  44. Bernabeu I, Aller J, Álvarez C, Fajardo C, Gálvez A, Guillín C, et al. Criterios para el diagnóstico y el control postcirugía de la acromegalia, y el cribado y el manejo de sus comorbilidades: recomendaciones de expertos. Endocrinol Diabetes Nutr. 2018;65(5):297-305.

  45. de Pablos P, Venegas E, Álvarez C, Fajardo C, de Miguel P, González N. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey. Pituitary. 2020;23(2):129-39.




2020     |     www.medigraphic.com